FindMyKOL
Clinical trialNCT03865654CompletedInterventional

Individualizing Surveillance Mammography for Older Breast Cancer Survivors

NCT03865654 is an interventional trial sponsored by Dana-Farber Cancer Institute. As of 18 Nov 2026, it is completed. It studies Breast Cancer. The registry lists an enrollment of 45 participants at 1 site in 1 country. The registry lists a start date of 16 May 2019 and a primary completion date of 1 Jul 2021.

View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT03865654
FieldValue
Registry IDNCT03865654
StatusCompleted
Study typeInterventional trial
Lead sponsorDana-Farber Cancer Institute
Enrollment45
Registered sites1
Countries1
ConditionsBreast Cancer
Start16 May 2019
Primary completion1 Jul 2021
Study completion1 Jul 2021
Last update posted24 Aug 2022

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This research is being conducted to develop consensus on surveillance mammography and follow-up for breast cancer survivors who are age ≥75.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Massachusetts, United States1 site
  • Dana-Farber Cancer Institute

    Boston

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusetts: 1 siteMA1Rhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Questions about NCT03865654

Each answer restates registry values shown on this page.

What is NCT03865654?

NCT03865654 is an interventional trial sponsored by Dana-Farber Cancer Institute. It studies Breast Cancer.

Who leads NCT03865654?

The registry names Rachel Freedman, MD, MPH (principal investigator, Dana-Farber Cancer Institute) as the overall official.

Where does NCT03865654 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

When did NCT03865654 end?

The registry lists a primary completion date of 1 Jul 2021 and a study completion date of 1 Jul 2021. The sponsor last updated the record on 24 Aug 2022.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.